Pronounced Regional Variation in Esketamine and Ketamine Prescribing to US Medicaid Patients
Alexia G. Aguilar, Burke A. Beauregard, Christopher P. Conroy, Yashoda T. Khatiwoda, Shantia M. E. Horsford, Stephanie D. Nichols, Brian J. Piper
medRxiv Preprint Server April 23, 2022 preprint DOI: 10.1101/2022.04.23.22274206 via medRxiv
Summary
AI-generated from the abstractKetamine and esketamine effectively treat treatment-resistant depression without the therapeutic delay typical of other antidepressants and do not increase suicidal thoughts or behaviors in adolescents and young adults. Esketamine received FDA approval in March 2019.
Study at a glance
| Characteristics | Review |
|---|---|
| Interventions | Ketamine Esketamine |
| Topics | Depression Esketamine Ketamine |
| Keywords | Depression treatment Rapid-acting treatments Mental health interventions |
| Citations | 2 |
| Key finding | Ketamine and esketamine are efficacious for treatment-resistant depression, lack a therapeutic delay, and do not increase risk for suicidal thoughts and behaviors in adolescents and young adults. |
Abstract
Background Ketamine and esketamine are efficacious for treatment resistant depression. Unlike other antidepressants, ketamine and esketamine lack a therapeutic delay and do not increase risk for suicidal thoughts and behaviors in adolescents and young-adults. Esketamine gained FDA approval in March of 2019.